Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06829537 · ClinicalTrials.gov registry record
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
A clinical trial, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- 1,143
- Enrollment target
NCT06829537 is a clinical trial that has completed, run by Corcept Therapeutics. The registered enrollment target is 1,143 participants.
The verdict
NCT06829537 has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- 1,143 participants
- Enrollment target
Study Summary
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. Non-fasting labs and a urine collection will also be done. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethasone the night before at 11 PM. Cortisol level and study labs will also be collected. After the lab results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting blood draw at 8 AM and scheduling of a non-contrast CT scan.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,143 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2026-01-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06829537
The ClinicalTrials.gov registry entry for NCT06829537 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06829537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06829537 about?
NCT06829537 is a clinical study titled "Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)". This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. Aft...
What is the current status of trial NCT06829537?
This trial is currently completed. The enrollment target is 1,143 participants. The study started on 2025-03-28. Estimated completion is 2026-01-23.
Who is sponsoring clinical trial NCT06829537?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.